# MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

> **NCT04129398** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 22 (actual)

## Conditions studied

- Cytomegalovirus Infection
- Cytomegalovirus Disease

## Interventions

- **DRUG:** Letermovir tablet
- **DRUG:** Letermovir IV

## Key facts

- **NCT ID:** NCT04129398
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-27
- **Primary completion:** 2022-10-06
- **Final completion:** 2022-10-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129398, "MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04129398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*